摘要
目的探讨MICAL-L2在WHOⅡ级、Ⅲ级胶质瘤中的表达及对患者预后的评估价值。方法收集2013年至2019年聊城市第二人民医院手术切除的成人原发WHOⅡ级、Ⅲ级脑胶质瘤标本96例,正常脑组织标本10例作为对照,利用免疫组化检测MICAL-L2在成人WHOⅡ级、Ⅲ级胶质瘤组织与正常脑组织中的表达情况,分析MICAL-L2与各临床病理参数的关系。Log-rank检验评估Kaplan-Meier曲线中的预后差异。单因素Cox回归分析和多因素Cox回归分析筛选潜在风险因素;受试者工作特征(ROC)曲线下面积(AUC)评估MICAL-L2对WHOⅡ级、Ⅲ级胶质瘤患者的预后价值。结果MICAL-L2在成人WHOⅡ级、Ⅲ级胶质瘤中的高表达率高于正常脑组织(P<0.05);其高表达与患者年龄、肿瘤病理级别、Ki-67高表达相关(P<0.001),Kaplan-Meier生存曲线显示MICAL-L2高表达患者的总生存期低于低表达患者(P<0.001);多因素Cox回归模型分析提示年龄>46.5岁、WHOⅢ级胶质瘤和MICAL-L2高表达是患者预后的独立危险因素(P<0.05)。ROC曲线显示MICAL-L2预测WHOⅡ级、Ⅲ级胶质瘤患者5年总生存期的AUC为0.837,说明其具有良好的预后预测能力。结论MICAL-L2在WHOⅡ级、Ⅲ级胶质瘤中存在高表达,与患者的不良预后相关,可能作为WHOⅡ级、Ⅲ级胶质瘤风险分层的新型生物学标志物,为新分子靶点的开发提供理论支持。
Objective To investigate the expression of MICAL-L2 in WHO gradeⅡ/Ⅲglioma and its prognostic assessment value.Methods A total of 96 cases of surgically resected adult primary WHO gradeⅡ/Ⅲglioma specimens from 2013 to 2019 at the Second People's Hospital of Liaocheng were collected,with 10 normal brain tissue specimens serving as controls.Immunohistochemistry(IHC)was employed to validate MICAL-L2 protein expression in WHO gradeⅡ/Ⅲglioma versus normal brain tissues.Associations between MICAL-L2 expression and clinicopathological parameters were analyzed.Prognostic differences in Kaplan-Meier curves were assessed using the Log-rank test.Univariate and multivariate Cox regression analyses were performed to identify potential risk factors.The prognostic value of MICAL-L2 in gradeⅡ/Ⅲglioma patients was evaluated by receiver operating characteristic(ROC)Area under the curve(AUG).Results MICAL-L2 protein expression was significantly elevated in 96 adult WHO gradeⅡ/Ⅲglioma tissues versus normal brain tissues(P<0.05).Elevated MICAL-L2 expression correlated significantly with the age of patients,the level of tumor pathology,and the high expression of Ki-67(P<0.01).The Kaplan-Meier survival curve indicated that the overall survival of patients with high expression of MICAL-L2 was lower than that of patients with low expression(P<0.001).Multivariate Cox regression model analysis revealed that age greater than 46.5 years,WHO gradeⅢglioma and high MICAL-L2 expression were independent risk factors for patient prognosis(P<0.05).The ROC curve demonstrated that MICAL-L2 achieved an area under the curve(AUC)of 0.837 in predicting the 5-year overall survival of WHO gradeⅡ/Ⅲglioma patients,indicating good prognostic predictive capability.Conclusions MICAL-L2 demonstrates elevated expression in WHO gradeⅡ/Ⅲglioma and exhibits a significant association with patient prognosis.It may serve as a novel biomarker for risk stratification in WHO gradeⅡ/Ⅲglioma and lays the theoretical foundation for developing new molecular therapeutic targets.
作者
王敏
周莉
田佳
温丽君
郑士耀
刘昆
WANG Min;ZHOU Li;TIAN Jia;WEN Lijun;ZHENG Shiyao;LIU Kun(Department of Pathology,the Second People's Hospital of Liaocheng Affiliated to Shandong First Medical University,Liaocheng 252600,China;Department of Neurosurgery,the Second People's Hospital of Liaocheng Affiliated to Shandong First Medical University,Liaocheng 252600,China)
出处
《中国肿瘤外科杂志》
2025年第6期597-602,共6页
Chinese Journal of Surgical Oncology
基金
山东省医药卫生科技项目面上项目(编号:202301041086)。
关键词
胶质瘤
MICAL-L2
WHO分级
免疫组织化学
预后
Glioma
Molecule interacting with CasL-L2
WHO classification
Immunohisto-chemistry
Prognosis
